Henry Schein (NASDAQ:HSIC) Given New $110.00 Price Target at BTIG Research

Henry Schein (NASDAQ:HSIC) had its target price raised by research analysts at BTIG Research from $100.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 23.28% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Monday. Morgan Stanley reissued an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Barclays restated an “overweight” rating and issued a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Stifel Nicolaus set a $95.00 price target on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Barrington Research set a $104.00 price target on Henry Schein in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $92.93.

Henry Schein Stock Down 0.3%

Shares of NASDAQ:HSIC opened at $89.23 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. Henry Schein has a 52-week low of $61.94 and a 52-week high of $92.18. The business’s 50 day simple moving average is $85.22 and its two-hundred day simple moving average is $79.26. The firm has a market cap of $9.94 billion, a P/E ratio of 26.01, a PEG ratio of 1.71 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The company had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the firm earned $1.10 earnings per share. Henry Schein’s revenue for the quarter was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, research analysts forecast that Henry Schein will post 5.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors have recently added to or reduced their stakes in HSIC. Ameriprise Financial Inc. raised its holdings in shares of Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can grew its holdings in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after purchasing an additional 2,087,666 shares during the period. Norges Bank purchased a new stake in Henry Schein in the fourth quarter worth $88,116,000. Southpoint Capital Advisors LP increased its position in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares during the period. 96.62% of the stock is owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.